Amgen Innovations Opens Applications for 2023 Call for Projects

Amgen Innovations is accepting applications from French research teams for its 2023 call for projects on innovative technologies and medical topics such as onco-haematology, cardiovascular issues and inflammatory diseases.

Amgen Inc is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. It is the world’s largest independent biotechnology firm and was founded in 1980 under its former name Applied Molecular Genetics Inc. Amgen operates worldwide: in North America, South America, Australia, Asia, Africa and Europe.

Amgen France administers a programme entitled Amgen Innovations which supports innovative initiatives to improve health; to improve patient and caregiver quality of life; and to support the competitiveness of France. In turn, Amgen Innovations manages the Fonds Amgen France pour la Science et l’Humain (Amgen France Fund for Science and Humanity). Its €3.6 million endowment will be used over three years to support health start-ups, research projects on therapeutic innovation and health professionals.

The call is based around a different topic each year. For 2023, the focus of the call for proposals is ‘Improving patient experiences: From precision medicine to optimising treatment plans’. The call is split into two components: basic research and health innovation. The basic research component will support research into onco-haematology, chronic inflammatory diseases and certain cardiovascular conditions. The health innovation component is focused on new technologies, including artificial intelligence and other digital solutions, as tools for improving the healthcare experience for patients.

Funding can be awarded to research teams, patient associations or health professionals. In all cases, the structure or organisation hosting the project must comply with the following French laws in order to receive funding:

  • Meet the conditions of article 238 of the General Tax Code (article 238 bis du Code général des Impôts).
  • Be eligible for the patronage scheme (dispositif de mécénat).
  • Be able to issue tax receipts.

The candidate’s organisation or structure must be based in metropolitan France or a French overseas territory (DROM COM).

A total of €600,000 has been allocated. Funding of a maximum of €75,000 over two years can be requested per project.

Applications must be submitted by 17 September 2023.

(This report was the subject of a ResearchConnect Newsflash.)